Nino Hallen
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study.
Journal: PharmacoEconomics - open
Published: April 12, 2021
Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 12, 2020
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Journal: Advances in therapy
Published: June 16, 2020
Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil.
Journal: Journal of medical economics
Published: May 07, 2020
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden.
Journal: Diabetologia
Published: April 22, 2020
Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel.
Journal: Value in health regional issues
Published: December 04, 2019
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 15, 2019
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Journal: Journal of medical economics
Published: October 16, 2019
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Journal: Applied health economics and health policy
Published: July 03, 2019
Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Journal: Diabetes, obesity & metabolism
Published: November 16, 2018
DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: March 07, 2018
Screening fathers for postpartum depression can be cost-effective: An example from Sweden.
Journal: Journal of affective disorders
Published: January 09, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026